Federation of Medical & Sales Representatives Association of India & Ors. v. Union of India & Ors.

Supreme Court of India • 08 October 2026 • 2026 INSC 1097

Case Summary
The Supreme Court directed the Union of India to constitute, within two weeks, its proposed committee to comprehensively examine unethical pharmaceutical marketing practices and the adequacy of the existing regulatory framework. The committee must consult petitioners, intervenors and other stakeholders and recommend an appropriate regulatory and/or statutory framework addressing transparency, accountability, monitoring and enforcement. It should endeavour to submit its recommendations within two months of its first meeting, after which the Union must take an appropriate and reasoned decision.

Coram: Justice Vikram Nath; Justice Sandeep Mehta

Area of Law: Constitutional Law / Public Health / Pharmaceutical Regulation — Article 21, Right to Health, Unethical Pharmaceutical Marketing, UCPMP

Citation: 2026 INSC 1097

Date: 08 October 2026

Legal Issue

Whether the existing framework regulating pharmaceutical marketing practices adequately protects the right to health under Article 21, particularly where pharmaceutical companies are alleged to provide gifts, hospitality, sponsored travel, monetary benefits and other inducements to healthcare professionals; and whether an effective and enforceable statutory/regulatory mechanism is required to ensure transparency, accountability and enforcement in pharmaceutical marketing.

Brief Facts

Case No.: Writ Petition (Civil) No. 323 of 2021.

The petition was instituted under Article 32 of the Constitution seeking protection of the fundamental right to health, which the Court recognised as an integral component of Article 21.

The petitioners alleged widespread unethical pharmaceutical marketing practices, including monetary benefits, gifts, hospitality, sponsored travel, entertainment and other inducements allegedly offered to medical practitioners to influence prescribing behaviour. They contended that such practices could contribute to irrational or excessive prescriptions, expensive branded medicines, adverse drug reactions and antimicrobial resistance.

The petitioners pointed to an alleged regulatory asymmetry: medical practitioners are subject to ethical restrictions regarding acceptance of gifts and benefits, while the pharmaceutical industry was principally governed by the Uniform Code for Pharmaceutical Marketing Practices (UCPMP). They sought statutory force for the Code or, alternatively, judicial guidelines until an effective law was enacted.

During the proceedings, the Union informed the Court that UCPMP 2024 had strengthened the existing framework through measures concerning disclosures, gifts, physician samples, CME activities, complaint mechanisms and oversight. The Government also proposed a three-member committee to examine whether further statutory/regulatory measures were necessary.

Held / Decision

The Supreme Court observed that the material before it indicated that the existing framework had not proved entirely effective in preventing and curbing unethical pharmaceutical practices.

However, the Court recognised that determining the precise statutory framework, regulatory oversight and enforcement mechanism primarily involves legislative and executive policy. Therefore, respecting the separation of powers, the Court declined to substitute its own policy determination for that of the executive.

Exercising jurisdiction under Articles 32 and 142, the Court directed:
1. The Union must constitute its proposed committee, if not already constituted, within two weeks.
2. The committee must comprehensively examine unethical pharmaceutical marketing practices and the adequacy of the existing regulatory and statutory framework.
3. Petitioners, intervenors and other relevant stakeholders must be given an opportunity to submit their views and suggestions.
4. The committee may obtain assistance from technical, professional and domain experts.
5. It should endeavour to submit recommendations to the Union within two months from its first meeting.
6. The Union must thereafter consider the recommendations and take an appropriate and reasoned decision.
7. A compliance affidavit must subsequently be filed before the Supreme Court.

The matter was directed to be listed on 29 January 2027 as part-heard.

Important Observations

The Court emphasised that merely having regulatory norms on paper is insufficient. The effectiveness of pharmaceutical regulation must also be assessed through its implementation, monitoring and enforcement.

It recognised a continuing need for an effective and enforceable framework governing pharmaceutical marketing practices, with adequate transparency and accountability.

At the same time, the Court drew an important constitutional boundary: formulation of the precise regulatory regime belongs primarily to the executive and legislative domain. Judicial review should ensure constitutional compliance and facilitate an effective process rather than have the Court itself formulate pharmaceutical policy.

The regulatory framework must balance legitimate pharmaceutical-industry interests against the overriding public interest in protecting patients and ensuring ethical, accessible and affordable healthcare.

Full Headnote

Constitution of India — Articles 21, 32 & 142 — Right to Health — Pharmaceutical Marketing Practices — Unethical Inducements to Medical Practitioners — UCPMP — Regulatory Framework — Separation of Powers: Petition under Article 32 seeking an effective and enforceable framework to regulate unethical pharmaceutical marketing practices, including alleged gifts, hospitality, sponsored travel, monetary benefits and other inducements capable of influencing prescription practices. Supreme Court observed that the existing framework had not proved entirely effective in preventing and curbing unethical practices and that efficacy of regulation must be assessed not merely by existence of norms but also by implementation, monitoring and enforcement. However, determination of the appropriate statutory framework, regulatory oversight and enforcement mechanism involves matters of legislative and executive policy, and the Court cannot substitute its own policy determination for that of the executive. Exercising powers under Articles 32 and 142 and having regard to the right to health under Article 21, Court directed Union of India to constitute its proposed Committee within two weeks to comprehensively examine the existing framework and unethical pharmaceutical marketing practices; consult petitioners, intervenors and other stakeholders; consider expert inputs; and recommend an appropriate regulatory and/or statutory framework ensuring transparency, accountability and effective enforcement. Committee to endeavour to submit recommendations within two months from its first meeting; Union thereafter to take an appropriate and reasoned decision and file compliance affidavit before the Court.

Legal Significance

This order is important because it connects regulation of pharmaceutical marketing directly with the constitutional right to health under Article 21, while simultaneously preserving the separation between judicial review and executive policymaking.

Rather than immediately judicially prescribing a binding pharmaceutical-marketing code, the Supreme Court created a time-bound, stakeholder-driven regulatory review process aimed at determining whether and how the existing framework should be strengthened through statutory or regulatory measures.

For pharmaceutical companies, healthcare professionals and compliance teams, the case is significant because it places particular emphasis on effective enforcement, transparency, accountability and monitoring, rather than formal existence of industry codes alone.

View Original Judgment

Disclaimer: This case summary and headnote are provided for informational and educational purposes. Readers should refer to the original judgment for the complete text and authoritative legal position.